• Molecular NameDobutamine
  • SynonymNA
  • Weight301.386
  • Drugbank_IDDB00841
  • ACS_NO34368-04-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.67
  • pka9.4
  • LogD (pH=7, predicted)0.65
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.16
  • LogSw (predicted, AB/LogsW2.0)5.28
  • Sw (mg/ml) (predicted, ACD/Labs)0.23
  • No.of HBond Donors4
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds7
  • TPSA72.72
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Its primary mechanism is direct stimulation of β1 receptors of the sympathetic nervous system.
  • Absorption_valueN/A
  • Absorption (description)Inactive after oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAfter IV administration, it is rapidly metabolised by glucuronide conjugation and 3-O-methylation to inactive metabolites which are excreted in the urine, mostly in the first 2 hours.
  • Half life2 min
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse events are increased heart rate, blood pressure, and ventricular ectopic activity, hypotension.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A